ESSAI CLINIQUE
    No essai
    ClinicalTrials.gov ID
Investigateur(trice) principal(e)
Coordonnateur(rice)
(EN) A Phase 2 Study of Blinatumomab in Combination With Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ? 1 to < 31 Years Old With First Relapse
    COG-AALL1821
    NCT04546399
     Actif en recrutement
CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
Leucémie lymphoide aiguë (LLA) Dr Yvan Samson